---
id: system-diabetes-remission-boundary-memo
type: system
topic: diabetes
last_compiled_at: 2026-04-24
owner: codex
status: active
language: en
verification_status: compiled
decision_grade: no
language_qa_status: light_checked
---

# Diabetes Remission Boundary Memo

- Date: `2026-04-24`
- Scope: `src-diabetes-007`, with treatment context from `src-diabetes-015`, `src-diabetes-024`

This memo exists to stop the diabetes module from turning remission into a simple protocol promise.

## Core Takeaway

`feline diabetic remission is real, but the current seed evidence does not support a single predictor, diet, insulin type, or protocol as the universal remission key`

The remission branch should be visible.

It should not be allowed to dominate the whole disease model.

## Boundary Source

The controlling source is:

- [src-diabetes-007 deep extraction round 1](src-diabetes-007-deep-extraction-round1.md)

That worksheet supports four useful facts:

- remission is possible in cats
- 22 studies were included in the systematic review
- evidence quality was moderate to poor
- no single factor predicts remission

## What Remission Is Allowed To Mean

Remission can mean:

- a high-value endpoint in scenario-appropriate feline diabetes studies
- a reason to track insulin independence or non-insulin-dependent state separately from short-term glycemic improvement
- a legitimate treatment goal when evidence and monitoring are explicit
- a branch that interacts with diet, insulin, obesity, pancreatitis, and endocrine-secondary disease

## What Remission Must Not Mean Yet

Remission should not mean:

- one diet formulation reliably causes remission
- one insulin type reliably predicts remission
- remission rates can be compared across studies without checking definitions and design
- remission potential erases chronic beta-cell failure or secondary endocrine disease
- non-insulin-dependence is automatically identical to a fully defined remission endpoint
- the primary endpoint for every feline diabetes project, including SGLT2 safety, complicated diabetes, or comparative-model questions

## Interaction With Diet And Insulin Sources

`src-diabetes-015` supports low-carbohydrate/low-fiber diet as a strong diet-comparison signal in a 16-week randomized owner-blinded study, but it does not replace the remission systematic review.

`src-diabetes-024` supports glargine U300 as promising in a small prospective study, but it does not establish insulin-protocol superiority.

So the current read is:

`diet and insulin choices matter, but remission claims defer to the systematic-review boundary`

## Operational Rule

When a diabetes page mentions remission, it should include one of these labels:

- `endpoint`: remission is being tracked as an outcome
- `conditional endpoint`: remission is high-value only for the specified study context
- `signal`: a study reports insulin independence or remission-like outcome
- `boundary`: evidence quality blocks protocol ranking
- `not established`: a predictor or hierarchy is being proposed but not yet source-supported

## Best Write-Back Targets

- [endpoint handbook](../../topics/diabetes/endpoint-handbook.md)
- [translation brief](../../topics/diabetes/translation-brief.md)
- [synthesis index](../../topics/diabetes/synthesis-index.md)
- [current state dashboard](../../topics/diabetes/current-state-dashboard.md)

## Promotion Judgment

- repeated? `yes`
- structurally clarifying? `yes`
- evidence-safe enough for this layer? `yes, for remission-boundary control; no, for protocol ranking`
- smallest durable home: `memo + endpoint write-back + translation write-back + dashboard write-back`

### Decision

- promote
